KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested Capital

AbCellera Biologics (ABCL) Equity Ratio (2020 - 2025)

AbCellera Biologics' Equity Ratio history spans 6 years, with the latest figure at 0.71 for Q3 2025.

  • For the quarter ending Q3 2025, Equity Ratio fell 8.15% year-over-year to 0.71, compared with a TTM value of 0.71 through Sep 2025, down 8.15%, and an annual FY2024 reading of 0.78, changed 0.24% over the prior year.
  • Equity Ratio for Q3 2025 was 0.71 at AbCellera Biologics, down from 0.72 in the prior quarter.
  • The five-year high for Equity Ratio was 0.85 in Q1 2021, with the low at 0.71 in Q3 2025.
  • Average Equity Ratio over 5 years is 0.78, with a median of 0.78 recorded in 2023.
  • Year-over-year, Equity Ratio dropped 10.59% in 2022 and then grew 6.39% in 2023.
  • Tracing ABCL's Equity Ratio over 5 years: stood at 0.78 in 2021, then rose by 2.89% to 0.8 in 2022, then fell by 3.25% to 0.77 in 2023, then increased by 0.24% to 0.78 in 2024, then decreased by 8.41% to 0.71 in 2025.
  • Per Business Quant, the three most recent readings for ABCL's Equity Ratio are 0.71 (Q3 2025), 0.72 (Q2 2025), and 0.76 (Q1 2025).